Cargando…

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment

OBJECTIVE: To test whether patients with MS on disease-modifying treatments (DMTs) are at a higher risk of acute or chronic hepatitis E virus (HEV) infections or extrahepatic manifestations, we monitored approximately 1,100 persons with MS (pwMS) during 3 years for HEV infection. METHODS: This is an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diebold, Martin, Fischer-Barnicol, Bettina, Tsagkas, Charidimos, Kuhle, Jens, Kappos, Ludwig, Derfuss, Tobias, Décard, Bernhard F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705628/ https://www.ncbi.nlm.nih.gov/pubmed/31454772 http://dx.doi.org/10.1212/NXI.0000000000000594

Ejemplares similares

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development
por: Meira, Maria, et al.
Publicado: (2016)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Acute Polyradiculomyelitis With Spinal Cord Gray Matter Lesions: A Report of Two Cases
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis
por: Cerdá-Fuertes, Nuria, et al.
Publicado: (2023)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Lymphocyte recovery after fingolimod discontinuation in patients with MS
por: Nagy, Sara, et al.
Publicado: (2020)

Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003)
por: Collongues, Nicolas, et al.
Publicado: (2020)

Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS
por: Oechtering, Johanna, et al.
Publicado: (2022)

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
por: Meira, Maria, et al.
Publicado: (2014)

Longitudinal patterns of cortical thinning in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2020)

PARP-1 deregulation in multiple sclerosis
por: Meira, Maria, et al.
Publicado: (2019)

Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients
por: Parmar, Katrin, et al.
Publicado: (2021)

Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities
por: Rose, Natalie, et al.
Publicado: (2022)

High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Longitudinal changes of deep gray matter shape in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2022)

Mass Cytometry of CSF Identifies an MS-Associated B-cell Population
por: Johansson, David, et al.
Publicado: (2021)

Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis
por: Ineichen, Benjamin V., et al.
Publicado: (2022)

The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2019)

Additive and interaction effects of working memory and motor sequence training on brain functional connectivity
por: Zuber, Priska, et al.
Publicado: (2021)

Growth differentiation factor 15 is increased in stable MS
por: Amstad, Andrea, et al.
Publicado: (2020)

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
por: Kuhle, Jens, et al.
Publicado: (2019)

Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis
por: Naegelin, Yvonne, et al.
Publicado: (2020)

Brain atrophy measurement over a MRI scanner change in multiple sclerosis
por: Sinnecker, Tim, et al.
Publicado: (2022)

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS
por: Zimmermann, Maria, et al.
Publicado: (2015)

Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis
por: Müller, Jannis, et al.
Publicado: (2022)

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2017)

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial
por: Kuhle, Jens, et al.
Publicado: (2023)

Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS
por: Boligan, Kayluz F., et al.
Publicado: (2020)

Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis
por: Oechtering, Johanna, et al.
Publicado: (2021)

Impact of complement activation on clinical outcomes in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2021)

Monitoring of radiologic disease activity by serum neurofilaments in MS
por: Uher, Tomas, et al.
Publicado: (2020)

α4-integrin receptor desaturation and disease activity return after natalizumab cessation
por: Derfuss, Tobias, et al.
Publicado: (2017)

Epstein-Barr–negative MS: a true phenomenon?
por: Dobson, Ruth, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f8t95e1q8k25nn5pqu6h0ff9rv